Clearmind Medicine Completes Dosing of 24 Participants in Phase I/II AUD Trial
CMND•Clearmind Medicine has dosed all 24 participants in cohorts 1 through 4 of its FDA-regulated Phase I/II trial of CMND-100 for Alcohol Use Disorder. Interim safety data from the first three cohorts show a strong profile, paving the way for Part B advancement under randomized, double-blind, placebo-controlled design.
1. Part A Dosing Completion
Clearmind Medicine announced the successful completion of dosing for all 24 participants across cohorts 1 through 4 in Part A of its Phase I/II trial of CMND-100 for Alcohol Use Disorder. This milestone marks the end of the initial healthy volunteer escalation phase under FDA oversight.
2. Trial Design and Sites
The multicenter, randomized, double-blind, placebo-controlled study treated healthy participants with escalating doses of CMND-100 at Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Rapid patient recruitment and efficient treatment timelines were achieved at all sites.
3. Safety Profile and Next Steps
Interim results from the first three cohorts demonstrate a strong safety profile, supporting the transition to Part B of the trial. Clearmind plans to initiate the next phase of dosing to evaluate CMND-100’s efficacy and pharmacodynamics in patients with Alcohol Use Disorder.
